Approaching Reactive Arthritis Associated With Poor Prognostic Factors: A Case Report and Literature Review
| Autor: | Swetha Ann Alexander, Ranadeep Mandhadi, Eunjung Kim |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty dactylitis 030204 cardiovascular system & hematology poor prognostic markers Dactylitis 03 medical and health sciences 0302 clinical medicine Rheumatology Sulfasalazine Internal medicine biologic therapies adalimumab medicine Adalimumab Internal Medicine In patient Reactive arthritis nsaid dmard glucocorticoids business.industry Biologic therapies General Engineering medicine.disease reactive arthritis Differential diagnosis business 030217 neurology & neurosurgery medicine.drug keratoderma blennorrhagicum |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | The aim of this paper is to review and discuss the background, common manifestations, differential diagnosis, and current treatment practices of reactive arthritis. The focus will be on the choice of therapy in patients with poor prognostic factors. A PubMed search was performed in March 2020 on reactive arthritis and revealed 137 articles. Fourteen case reports and four large-scale studies that are pertinent for discussion in terms of treatment of reactive arthritis over the past five years are reported along with poor prognostic markers. The first choice of therapy regardless of the number of poor prognostic markers is non-steroidal anti-inflammatory drugs (NSAIDs). The second choice of therapy appeared to be glucocorticoids in the oral as well as intra-articular forms. No correlation was detected between the need for systemic steroids and the number of poor prognostic factors present. The third choice of therapy appears to be disease-modifying anti-rheumatic drugs (DMARDs) (such as sulfasalazine) and their increasing use can be demonstrated over time. Novel therapies such as adalimumab have also been shown to be used and this shows a strong correlation with an increased number of poor prognostic factors. Reporting of these case reports and review of literature contribute to knowing more about reactive arthritis and help keep us up to date with newer therapies available when patients do not respond to conventional therapy. It was notable that the increased number of poor prognostic factors and non-responders have shown increased use of tumor necrosis factor inhibitors (TNFI) such as adalimumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|